As TP53 disruption was rare (5% of tested patients) and unknown in 45% of patients, we also examined the independent effect of CLL-CI in the 300-patient full cohort when adjusting for disease stage, the only non-CIRS feature significantly related to EFS and recorded in all patients (Table 2). The gene discussed is TP53; the disease is B-cell chronic lymphocytic leukemia.